Navigation Links
Disease progression model of pancreatic cancer developed by Penn researchers

Building on previous work, researchers at the University of Pennsylvania School of Medicine have developed an animal model of pancreatic cancer that closely mimics disease progression in humans. From this, they hope to develop new treatments for this deadly disease. Advanced pancreatic cancer is among the most lethal of cancers, with a one-year survival rate after chemotherapy of only 17 to 28 percent of patients, according to the National Cancer Institute.

Sunil R. Hingorani, MD, PhD, and David A. Tuveson, MD, PhD, both in the Departments of Medicine and Cancer Biology, and colleagues, engineered mice to express two mutant genes commonly associated with pancreatic cancer: Kras, an oncogene, and p53, a well-studied tumor suppressor. The investigators linked physiological, cellular, and genomic changes due to mutations in Kras and p53 in the mice to changes similar to that observed in pancreatic cancer patients. They report their findings in the May issue of Cancer Cell.

The disease that develops in the Kras and p53 mutant mouse model demonstrates distinct similarities to human pancreatic cancer at multiple levels. "In terms of clinical presentation, metastatic burden, and histological changes in tissue, this model appears to closely mimic the human disease," says Hingorani.

Clinical symptoms in the mutant mice mirrored those displayed in pancreatic cancer patients, such as abdominal swelling and muscle loss. Similarly, the progression of pancreatic cancer metastases paralleled that seen in the human disease. "In this model, pancreatic cancer metastasizes to the liver, lungs, diaphragm, and adrenal glands, all the same places that human pancreatic cancer metastasizes," says Tuveson.

The frequency of metastases to these various organ sites was also highly similar to that seen in humans. In human patients, 60 to 80 percent develop metastases to the liver; and 50 to 60 percent develop metastases to the lungs. In the genetically modified an
'"/>

Source:University of Pennsylvania


Page: 1 2 3

Related biology news :

1. Transplantation Of Monkey Embryonic Stem Cells Reverses Parkinson Disease In Primates
2. Finding Cures For Tropical Diseases: Is Open Source An Answer?
3. Protein Packages Found To Activate Genes; May Be What Regulates Development And Disease
4. Study: Soap And Water Work Best In Ridding Hands Of Disease Viruses
5. Gene Therapy For Parkinsons Disease Moves Forward In Animals
6. Duke Chemists Isolating Individual Molecules Of Toxic Protein In Alzheimers, Parkinsons Disease
7. Discovery Promises Simpler Therapy for Sickle Cell Disease
8. WHO Warns Of Increased Risk Of Vector-borne Diseases In Tsunami-affected Areas
9. Gene Therapy Cures Inherited Liver Disease In Rats
10. Disease diagnosis, biodefense among UH chemical research projects
11. Infants With Rare Genetic Disease Saved by Cord Blood Stem Cells

Post Your Comments:
(Date:11/23/2009)...for 360 million years and survived when the dinosa...g to make many of them extinct, according to an ar... . , The fungus, Batrachochytrium dendrobatidi...amphibian extinctions in Central America and north...350 amphibian species by penetrating their skin, b...
(Date:11/23/2009)...x-week-old turkey poults could save millions of ma...ccording to Dr. Gerald Steiner from the Dresden Un...eir use of infrared spectroscopy to determine the ...accurate method with the potential to be used by t... eggs for breeding. The pilot study has just been ...
(Date:11/23/2009)... Interuniversity Professorship in Law and the Huma...of the Basque Country. The Professorship is largel...ch as researchers in the fields of molecular biolo...he Interuniversity Professorship in Law and the Hu...Basque Country was created in 1993. The worldwide ...
Breaking Biology News(10 mins):Rescuing male turkey chicks 2Research and legislation should go hand in hand, as much as possible 2Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 1Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 2Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 3Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 4Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 5Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 6Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 7Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 8Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 9Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 10Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 11Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 12Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 13Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 14Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 15Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 16Inverness Medical Innovations Announces Third Quarter 2009 Results 5731 17Intercept Pharmaceuticals Announces Positive Phase II Results for INT 747 as a Treatment for Primary Biliary Cirrhosis 5726 1Intercept Pharmaceuticals Announces Positive Phase II Results for INT 747 as a Treatment for Primary Biliary Cirrhosis 5726 2Intercept Pharmaceuticals Announces Positive Phase II Results for INT 747 as a Treatment for Primary Biliary Cirrhosis 5726 3Success Targeting Competencies Missed in Traditional Testing Leads to Selection of Amistaff for Poster Presentations on Prophecy 26apos 3Bs Video Base 60135 1Success Targeting Competencies Missed in Traditional Testing Leads to Selection of Amistaff for Poster Presentations on Prophecy 26apos 3Bs Video Base 60135 2Success Targeting Competencies Missed in Traditional Testing Leads to Selection of Amistaff for Poster Presentations on Prophecy 26apos 3Bs Video Base 60135 3Success Targeting Competencies Missed in Traditional Testing Leads to Selection of Amistaff for Poster Presentations on Prophecy 26apos 3Bs Video Base 60135 4
...in, reward and addictive behaviors. Opioids exert ... receptors, mu, delta and kappa whose genes have b...Opioid receptors in the brain are activated by a f...orphins and endorphin, which are released by neuro...usly by alkaloid opiates, the prototype of which i...
...ry J. Hannon, Ph.D., Cold Spring Harbor Laboratory...ute (HHMI) investigator, along with two other youn...rial Sloan-Kettering Cancer Centers (MSKCC) 2007 P... named after Paul A. Marks, Ph.D., President Emeri... to the basic understanding and treatment of cance...
...m aimed at linking together the world,s databases ... the Nobel Prize for Medicine awarded to Mario R. ... launched this week. , The Cambridge University... will ultimately support new medical advances and ...esearch. , Because they are so genetically simila...
Other Biology News:How does the opioid system control pain, reward and addictive behavior? 2How does the opioid system control pain, reward and addictive behavior? 3How does the opioid system control pain, reward and addictive behavior? 4Gregory Hannon wins 2007 Paul Marks Prize for contributions to understanding and treating cancer 2A computer for your mouse! 2
(Date:11/24/2009)...leEnergyCorp.announcedtodaythatthecompanyandtheOde...rded$2millionbyWashingtonState,sCommunityEconomicR...iptoconstructthestate,sfirstspecialtybiochemicalbi...willsignificantlyspeedthedevelopmentofourbiorefine...MarbleEnergyCEOKellyOgilvie."WearegratefultotheGov...
(Date:11/24/2009)...patientswithadvanced-stage,orrecurrentendometrialc...ll/-AEternaZentarisInc.(NASDAQ: AEZS ;TSX:AEZ)(the...nendocrinetherapyandoncology,todayannouncedpositiv...xicpeptideconjugate,AEZS-108(formerlyAN-152),inpat...ersonalizedhealthcareapproach,thestudyselectedpati...
(Date:11/24/2009)...ll/--Shireplc(LSE:SHP,NASDAQ: SHPGY ),theglobalsp...tithassubmittedaMAAtotheEuropeanMedicinesAgencyfor...erapyindevelopment,forthetreatmentofType1Gaucherdi...ucerasealfathathasbeensubmitted,withprevious,submi...lobalsupplyshortageofthecurrentlyapprovedandmarket...
(Date:11/24/2009)...-FirstCall/--GenomicHealth,Inc.(Nasdaq: GHDX )toda...hairman,willpresentatthe21stAnnualPiperJaffrayHeal...009at10:00a.m.ET. ,, Toaccesstheliveandsubseque...torRelationssectionofGenomicHealth,swebsiteat http...ebsiteatleast15minutespriortothebeginningofthepres...
Breaking Biology Technology:Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Genomic Health to Present at Piper Jaffray Health Care Conference 2
...need is a good idea to make some good money. You c...me registration for a year for much less than $1 a...per month. For an additional $3 a month, get an en...fer secure online credit-card transactions. Cha-ch...n in for free. In principle you will have almost t...
...s. The Madison police department has moved to sp...ddition of an eToken USB key system provided by A...vide a robust and dependable situation thats easil...focus on protecting the city of Madison with unpar...on, said Neil Sullivan, the companys enterprise se...
...fices are located in the MG&E Innovation Center at...al research group ConjuGon announced on Tuesday ...of $1.1 million dollars from angel investors, incl...e new funds will be directed to the firms operatin...otheraputic treatments. , ,ConjuGon develops remed...
Other Biology Technology:The Wal-Mart-ization of e-commerce 2The Wal-Mart-ization of e-commerce 3Madison police adopt digital lock and key 2ConjuGon lands $1 million angel investment 2
Rabbit Anti-Potassium Channel kv3.2 Antibody, Unconjugated from Spring Bioscience
Sheep Anti-Human ErbB 2 Polyclonal Antibody, Unconjugated from Abcam
Hybridization Solution, 2 Concentrate, Buffered with SSPE from Sigma-Aldrich
Rabbit Anti-Rat Potassium Channel Kv2.2 Antibody, Unconjugated from CHEMICON
Biology Products: